RENAL AND DEPRESSOR EFFECTS OF SQ-29,072, A NEUTRAL ENDOPEPTIDASE INHIBITOR, IN CONSCIOUS HYPERTENSIVE RATS

被引:46
作者
SEYMOUR, AA
NORMAN, JA
ASAAD, MM
FENNELL, SA
SWERDEL, JN
LITTLE, DK
DORSO, CR
机构
[1] Department of Pharmacology, Squibb Institute for Med. Res., Princeton, NJ 08543-4000
关键词
D O I
10.1097/00005344-199007000-00022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The depressor and renal responses to the neutral endopeptidase (NEP) inhibitor, SQ 29,072, were characterized in both the conscious spontaneously hypertensive rat (SHR) and the conscious deoxycorticosterone acetate (DOCA)/salt hypertensive rat. Inhibition of tissue NEP activity by pharmacologically active doses was also ascertained in both hypertensive models. Intravenous administration of 300 μmol/kg of SQ 29,072 significantly reduced mean arterial pressure (MAP), produced modest natriuretic and diuretic responses, and inhibited renal NEP activity by approximately 40% in conscious SHR. Doses of 100 and 300 μmol/kg of SQ 29,072 elicited greater depressor responses (-36 ± 7 and -41 ± 8 mm Hg, respectively) in DOCA/salt hypertensive rats than in SHR (-11 ± 24 and -31 ± 5 mm HG, respectively). SQ 29,072 (300 μmol/kg, i.v.) also inhibited renal NEP activity to a greater extent (70%) in DOCA/salt hypertensive rats. Similarly, the depressor responses to exogenous ANP 99-126 (1,3, and 10 nmol/kg, i.v.) were greater in DOCA/salt hypertensive rats (-16 ± 4, -38 ± 6, and -73 ± 6 mm Hg, respectively) than in the SHR (0 ± 6, -17 ± 3, and -24 ± 3 mm Hg, respectively). Finally, equidepressor doses of SQ 29,072 and ANP 99-126 both increased urine volume as well as sodium and cyclic GMP excretion in conscious DOCA/salt hypertensive rats. In conclusion, the profile of depressor and renal activities produced by SQ 29,072 was consistent with potentiation of endogenous ANP by inhibition of NEP in conscious SHR and DOCA/salt hypertensive rats.
引用
收藏
页码:163 / 172
页数:10
相关论文
共 29 条
[1]   PULMONARY EXTRACTION OF IMMUNOREACTIVE ATRIAL NATRIURETIC FACTOR IN DOGS [J].
BATES, ER ;
MCGILLEM, MJ ;
MANCINI, GBJ ;
GREKIN, RJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1989, 63 (05) :372-373
[2]  
CROZIER IG, 1986, HYPERTENSION, V8, P11
[3]  
HAMET P, 1986, J HYPERTENS, V4, pS49
[4]   CARBOXYALKYL DIPEPTIDES WITH ATRIAL NATRIURETIC FACTOR POTENTIATING AND ANTIHYPERTENSIVE ACTIVITY [J].
HASLANGER, MF ;
SYBERTZ, EJ ;
NEUSTADT, BR ;
SMITH, EM ;
NECHUTA, TL ;
BERGER, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (04) :737-739
[5]   CLEARANCE OF ATRIAL NATRIURETIC FACTOR BY LUNG, LIVER, AND KIDNEY IN HUMAN-SUBJECTS AND THE DOG [J].
HOLLISTER, AS ;
RODEHEFFER, RJ ;
WHITE, FJ ;
POTTS, JR ;
IMADA, T ;
INAGAMI, T .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (02) :623-628
[6]  
KOEHN JA, 1987, J BIOL CHEM, V262, P11623
[7]  
KRIETER PA, 1989, DRUG METAB DISPOS, V17, P14
[8]   RENAL AND BLOOD-PRESSURE RESPONSES TO SYNTHETIC ATRIAL NATRIURETIC FACTOR IN SPONTANEOUSLY HYPERTENSIVE RATS [J].
MARSH, EA ;
SEYMOUR, AA ;
HALEY, AB ;
WHINNERY, MA ;
NAPIER, MA ;
NUTT, RF ;
BLAINE, EH .
HYPERTENSION, 1985, 7 (03) :386-391
[9]   REGULATION OF GUANYLATE-CYCLASE BY ATRIAL-NATRIURETIC-FACTOR AND THE ROLE OF CYCLIC-GMP IN VASODILATION [J].
MURAD, F ;
LEITMAN, DC ;
BENNETT, BM ;
MOLINA, C ;
WALDMAN, SA .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1987, 294 (03) :139-143
[10]   SPECIFIC INHIBITORS OF ENDOPEPTIDASE 24.11 INHIBIT THE METABOLISM OF ATRIAL NATRIURETIC PEPTIDES INVITRO AND INVIVO [J].
OLINS, GM ;
KRIETER, PA ;
TRAPANI, AJ ;
SPEAR, KL ;
BOVY, PR .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1989, 61 (02) :201-208